English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Materials and methods Retrospective review of patients treated with pamidronate from January 1995 to June 2006 in Sant Joan de Deu hospital (Spain). Patients:younger than 18 years that underwent treatment with the protocol for at least one year and with z-score < -2.5, fractures and z-score < -1 or documented bone pain with z-score < -1. They were classified into 4 groups: osteogenesis imperfecta, chronic treatment with steroids, disuse and other conditions. Interventions: single intravenous administration of pamidronate (30 mg in prepubescent patients and 60 mg in all other patients) every six months. Clinical, radiological data and bone mineral density were obtained basal and after each cycle. For each patient the ratio fractures/year during the treatment and the total increase in z-score (total ΔZ) after the treatment were calculated.

pediatric rheumatology online journal

Treatment of the low bone mineral density with intravenous pamidronate in pediatric patients: review of a protocol of a single-day infusion twice a year